NCT02244489

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 1b Study Evaluating Momelotinib Combined With Capecitabine and Oxaliplatin in Subjects With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Sierra Oncology LLC - a GSK company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, tolerability, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma.

Conditions

• Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Momelotinib (MMB)	Momelotinib (MMB) tablet(s) administered orally once or twice daily
DRUG	Capecitabine	Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
DRUG	Oxaliplatin	Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.

Timeline

• Start date: 2014-11-05
• Primary completion: 2017-03-08
• Completion: 2017-04-05
• First posted: 2014-09-19
• Last updated: 2019-02-01

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study